UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

Form 8-K
 
Current Report
 Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): July 26, 2012

PLURISTEM THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)

Nevada
 
001-31392
 
98-0351734
(State or other jurisdiction of incorporation)
 
(Commission file number)
 
(I.R.S. Employer Identification Number)
 
MATAM Advanced Technology Park
Building No. 20
Haifa, Israel 31905
(Address of principal executive offices)
 
Registrant’s telephone number, including area code: 011 972 74 710 7171
 
N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 
 
Item  8.01 Other Events.
 
On July 26, 2012, the registrant announced that it had received an invitation from the U.S. National Institute of Allergy and Infectious Diseases (“NIAID”), to submit its PLacental eXpanded (PLX) cells to the NIAID for evaluation in models of hematopoietic and gastrointestinal acute radiation syndrome.
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
PLURISTEM THERAPEUTICS INC.
 
     
Date: July 26, 2012
By:
/s/ Yaky Yanay
 
   
Yaky Yanay
 
   
Chief Financial Officer